Contineum Therapeutics, Inc. (CTNM) stock
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.86+0.08 (+0.82%)
Close on Nov 13, 2026Market cap $370.94MP/E –Yield –
Contineum Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Contineum Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $48.10M, down 4.8% year over year. For fiscal 2025 it was $51.52M, up 34.1% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.52M | +34.1% |
| FY2024 | Dec 31, 2024 | $38.42M | +39.2% |
| FY2023 | Dec 31, 2023 | $27.60M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.70M | -9.7% |
| Q1 FY2026 | Mar 31, 2026 | $11.65M | -15.1% |
| Q4 FY2025 | Dec 31, 2025 | $12.76M | -2.0% |
| Q3 FY2025 | Sep 30, 2025 | $10.99M | +13.0% |
| Q2 FY2025 | Jun 30, 2025 | $14.06M | +78.0% |
| Q1 FY2025 | Mar 31, 2025 | $13.71M | +76.3% |
| Q4 FY2024 | Dec 31, 2024 | $13.02M | +62.4% |
| Q3 FY2024 | Sep 30, 2024 | $9.73M | +49.7% |
| Q2 FY2024 | Jun 30, 2024 | $7.90M | -16.5% |
| Q1 FY2024 | Mar 31, 2024 | $7.78M | +114.2% |
| Q4 FY2023 | Dec 31, 2023 | $8.01M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.50M | – |
| Q2 FY2023 | Jun 30, 2023 | $9.46M | – |
| Q1 FY2023 | Mar 31, 2023 | $3.63M | – |
See a number that looks wrong?